Pharmaceutical firm Suven Life Sciences has been granted four product patents — one each by Australia and Hong Kong and two by Japan for treatment of neurodegenerative diseases.
Neurodegenerative diseases include Alzheimer’s disease, Schizophrenia and Parkinson’s disease.
In a BSE filing, the company said it has been “granted one product patent from Australia, two product patents from Japan and one product patent from Hong Kong corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with neurodegenerative diseases.”
These patents are valid through 2030, the company said.
Suven Life Sciences CEO Venkat Jasti said: “We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena that are being developed for Major Depressive Disorder (MDD) with high un-met medical need with huge market potential globally.”
With these new patents, Suven has a total of 19 granted patents from Australia, 14 from Japan and 15 from Hong Kong.